Cisplatin-loaded PLGA Nanoparticles for HER2 Targeted Ovarian Cancer Therapy

Publication date: Available online 6 March 2019Source: Colloids and Surfaces B: BiointerfacesAuthor(s): Rossina Domínguez-Ríos, Dante R. Sánchez-Ramírez, Kassandra Ruiz-Saray, Paola E. Oceguera-Basurto, Mario Almada, Josué Juárez, Abraham Zepeda-Moreno, Alicia del Toro-Arreola, Antonio Topete, Adrián Daneri-NavarroAbstractThe conventional treatment (cytoreduction combined with cisplatin/carboplatin and taxane drugs) of ovarian cancer has a high rate of failure and recurrence despite a favorable initial response. This lack of success is usually attributed to the development of multidrug resistance mechanisms by cancer cells and avoidance of the anti-growth effects of monoclonal targeted therapeutic antibodies. The disease, like other cancers, is characterized by the overexpression of molecular markers, including HER2 receptors. Preclinical and clinical studies with trastuzumab, a HER2-targeted therapeutic antibody, reveal a low improvement of the outcomes of HER2 positive ovarian cancer patients. Therefore, here, we propose a cisplatin-loaded, HER2 targeted poly(lactic-co-glycolic) nanoplatform, a system capable to escape the drug-efflux effect and to take advantage of the overexpressed HER2 receptors, using them as docks for targeted chemotherapy. The NP/trastuzumab ratio was determined after fluorescein labeling of antibodies and quantification of fluorescence in NPs. The system was also characterized in terms of size, zeta potential, drug release kinetics, cytotoxici...
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research